In this episode, we discuss the diagnosis and management/monitoring of Clonal Cytopenias of Unknown Significance (CCUS) with Dr. Uma Borate. We also discuss the emerging data on risk stratification and key trials in this space that are currently ongoing. Here are the shownotes:
1. CCUS and risk of transformation to myeloid neoplasms:
https://www.sciencedirect.com/science/article/pii/S0006497121013471
2. Prediction of risk for myeloid neoplasms in clonal hematopoiesis:
3. CHRS risk score:
4. Germline predisposition to clonal hematopoiesis:
5. Cancer therapy shapes the fitness landscape of clonal hematopoiesis:
6. Canakinumab for the prevention of progression to cancer in patients with Clonal Cytopenias of Unknown Significance, IMPACT Study:
7. Ivosidenib in patients with CCUS and mutations in IDH1:
What is Blood Cancer Talks?
This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk